Pembrolizumab Treatment-Induced Liver Toxicity
Abstract: T cells play a critical role in immune responses against neoplasm. This finding contributed to the immunotherapy development, an effective treatment for many cancers nowadays. Programmed cell death protein 1 (PD1) is an inhibitory receptor on T cells which downregulate T-cell function per ligation with its ligands (PDL1 and PDL2). PD1 blockade is used to enhance antitumor immunity. Pembrolizumab is a humanized monoclonal anti-PD1 antibody currently used in the management of melanoma, non-small-cell lung cancer, and Hodgkin lymphoma. Most of the treatment toxicities are immune-related adverse events, but grade 3–4 toxicities occur in up to 5% of patients, mainly dermatologic. We present a case of grade 4 pembrolizumab-induced liver toxicity associated with an excellent treatment response in a Caucasian woman.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Pembrolizumab Treatment-Induced Liver Toxicity ; volume:15 ; number:2 ; year:2021 ; pages:742-750 ; extent:9
Case reports in gastroenterology ; 15, Heft 2 (2021), 742-750 (gesamt 9)
- Urheber
-
Calderon, Benoît
Stancu, Alma
Vanel, François-Roger
Vazquez, Léa
- DOI
-
10.1159/000518128
- URN
-
urn:nbn:de:101:1-2409120017563.383672224039
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
10.03.2026, 07:25 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Calderon, Benoît
- Stancu, Alma
- Vanel, François-Roger
- Vazquez, Léa
Ähnliche Objekte (12)
Pembrolizumab Treatment-Induced Liver Toxicity
Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
Pembrolizumab-Induced Delayed-Onset Hepatitis
Pembrolizumab-Induced Toxic Epidermal Necrolysis
Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge
Pembrolizumab
A toxicogenomic- and pharmacovigilance-based evaluation of drug-induced liver toxicity
Protective effect of silymarin on tacrolimus-induced kidney and liver toxicity
Pre-administration of turmeric prevents methotrexate-induced liver toxicity and oxidative stress
Hepatoprotective role of liver fatty acid binding protein in acetaminophen induced toxicity
Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model
Pembrolizumab Treatment-Induced Liver Toxicity
Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
Pembrolizumab-Induced Delayed-Onset Hepatitis
Pembrolizumab-Induced Toxic Epidermal Necrolysis
Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge
Pembrolizumab
A toxicogenomic- and pharmacovigilance-based evaluation of drug-induced liver toxicity
Protective effect of silymarin on tacrolimus-induced kidney and liver toxicity
Pre-administration of turmeric prevents methotrexate-induced liver toxicity and oxidative stress
Hepatoprotective role of liver fatty acid binding protein in acetaminophen induced toxicity
Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model
Pembrolizumab Treatment-Induced Liver Toxicity
Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
Pembrolizumab-Induced Delayed-Onset Hepatitis
Pembrolizumab-Induced Toxic Epidermal Necrolysis
Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge
Pembrolizumab
A toxicogenomic- and pharmacovigilance-based evaluation of drug-induced liver toxicity
Protective effect of silymarin on tacrolimus-induced kidney and liver toxicity
Pre-administration of turmeric prevents methotrexate-induced liver toxicity and oxidative stress
Hepatoprotective role of liver fatty acid binding protein in acetaminophen induced toxicity